Evelyn Eccles, MD
Family Medicine · Manchester, MINPI 1366533689
Payments from drug & device makers
Across 365 payments — averaging $18.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Pfizer$942
- Lilly USA, LLC$813
- Amgen$572
- AbbVie$365
- Novo Nordisk$357
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,899100%
- Education$230%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 79 | $1,463 |
| Pfizer | 50 | $942 |
| Lilly USA, LLC | 50 | $813 |
| Amgen | 28 | $572 |
| AbbVie | 20 | $365 |
| Novo Nordisk | 18 | $357 |
| GSK | 13 | $312 |
| Biohaven Pharmaceutical Holding Company Ltd. | 12 | $292 |
| Mylan Specialty L.p. | 10 | $204 |
| E.r. Squibb & Sons, L.L.C. | 10 | $199 |
| Novartis | 9 | $187 |
| Boehringer Ingelheim | 9 | $175 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $143 |
| Biohaven Pharmaceuticals, Inc. | 8 | $130 |
| Axsome Therapeutics, Inc. | 3 | $99 |
| Dexcom, Inc. | 2 | $89 |
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| Sanofi Pasteur Inc. | 3 | $63 |
| Johnson & Johnson | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| OWP Pharmaceuticals, Inc. | 2 | $40 |
| Nestle Healthcare Nutrition Inc. | 2 | $30 |
| Verona Pharma, Inc. | 1 | $28 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Abbott | 1 | $20 |
| Biomarin Pharmaceutical Inc. | 1 | $17 |
| Cranial Technologies, Inc | 1 | $17 |
| Viatris Specialty LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
| Merck | 1 | $13 |
| Indivior Inc. | 1 | $11 |
| Daiichi Sankyo Inc. | 1 | $11 |
How this compares
$6,922 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $115,096 |
| MounjaroTirzepatide | 35 | $65,977 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 78 | $65,694 |
| OzempicSemaglutide | 41 | $52,004 |
| JardianceEmpagliflozin | 38 | $45,317 |
| XareltoRivaroxaban | 47 | $40,639 |
| TrulicityDulaglutide | 19 | $36,332 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $25,575 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $23,868 |
| FarxigaDapagliflozin Propanediol | 23 | $22,328 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 24 | $21,794 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $20,355 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,635 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 56 | $8,925 |
| Tiotropium Bromide | 12 | $6,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $942 | $115,096114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $813 | $102,31054 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $312 | $95,684116 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $175 | $67,11162 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $1,463 | $52,71664 claims |
| Novo NordiskOzempic | $357 | $52,00441 claims |
| Johnson & JohnsonXarelto | $52 | $40,63947 claims |
| AbbVieSynthroid | $365 | $2,13424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.
Other family medicine in Manchester
- Derrick WilliamsonSouthfield$9.9M
- Rebecca RivardRoseville$7M
- Paul BensonBerkley$4.2M
- Michael HafranEast Lansing$2.7M
- Mitzie HewittBuckley$1.3M
- Loren ChudlerSouthfield$1.3M
- Solomon AmsterWhite Lake$981K
- Matt RosenbergJackson$559K
- Rhonda MejeurGrand Rapids$493K
- Steve LasaterSaint Johns$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.